loader from loading.io

Understanding Rett Syndrome - Part 2

Neurology Minute

Release Date: 05/27/2026

Lab Minute: Susac Syndrome and Behçet Disease show art Lab Minute: Susac Syndrome and Behçet Disease

Neurology Minute

In this lab minute, Dr. Stacey Clardy discusses Susac syndrome and Behçet disease. 

info_outline
Lab Minute: Human Prion Disease show art Lab Minute: Human Prion Disease

Neurology Minute

In this lab minute, Dr. Stacey Clardy discusses human prion disease. 

info_outline
Lab Minute: Human Prion Disease show art Lab Minute: Human Prion Disease

Neurology Minute

In this lab minute, Dr. Stacey Clardy discusses human prion disease. 

info_outline
July 2026 President Spotlight: Mid-Year Update show art July 2026 President Spotlight: Mid-Year Update

Neurology Minute

In the July episode of the President's Spotlight, Dr. Jason Crowell and Dr. Natalia Rost provide a mid-year review of the AAN’s progress, highlighting advocacy successes and the growing momentum for brain health worldwide.  Stay informed by watching the  video.  

info_outline
Preparing ALS Clinics to Provide Longitudinal Care for Individuals Carrying ALS Risk Variants show art Preparing ALS Clinics to Provide Longitudinal Care for Individuals Carrying ALS Risk Variants

Neurology Minute

Dr. Derek Stitt and Dr. Jennifer Morganroth discuss why identifying carrier status is so important.  Show citation:  Morganroth J, Yasek J, Harms M. Preparing Amyotrophic Lateral Sclerosis Clinics to Provide Longitudinal Care for Individuals Carrying ALS Risk Variants. Neurol Genet. 2026;12(4):e200406. Published 2026 Jun 24. doi:  

info_outline
When Drug Marketing Masquerades as Clinical Trials show art When Drug Marketing Masquerades as Clinical Trials

Neurology Minute

Dr. Justin Abbatemarco and Sukhun Kang discuss seeding trials and other hidden marketing tactics in clinical trials, and their implications for clinical practice and patient care.  Show citation:  Kang S, Lin I, Ekblom M, and Chang S. Clinical trials that are actually marketing ploys targeting doctors – how seeding trials put profit over patients. The Conversation. 2026;6(5). doi:

info_outline
The DRAIN Trial  show art The DRAIN Trial

Neurology Minute

Dr. Margarita Fedorova discusses the DRAIN trial and the efficacy of acetazolamide in idiopathic normal pressure hydrocephalus.  Show citation:  Virhammar J, Fasth O, Ekblom M, et al. Safety, tolerability, and efficacy of acetazolamide in idiopathic normal pressure hydrocephalus (DRAIN) in Sweden: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2026;25(6):550-559. doi: 

info_outline
Diagnosis and Management of Headache show art Diagnosis and Management of Headache

Neurology Minute

Dr. Matthew Robbins discusses the assessment and diagnosis of headache in emergency settings, emphasizing red and green flags to differentiate primary from secondary headaches. This episode provides practical tips for trainees and clinicians to improve headache management. Show citation:  Robbins MS. Diagnosis and Management of Headache: A Review. JAMA. 2021;325(18):1874-1885. doi:  

info_outline
Navigating the Transition From Pediatric to Adult Epilepsy Care - Part 2 show art Navigating the Transition From Pediatric to Adult Epilepsy Care - Part 2

Neurology Minute

In the second episode of this series, Dr. Dara Albert and Dr. Scott Perry discuss common barriers to transitioning from pediatric to adult care and share practical strategies clinicians can use to support successful patient transitions. Show citation:  Perry MS, Nascimento FA, Pina-Garza JE, et al. Addressing Barriers to Transitioning Pediatric Patients With Epilepsy to Adult Health Care in the United States: A Narrative Review. Neurol Clin Pract. 2026;16(3):e200616. doi: 

info_outline
Neurology® at 75: The Evolution of the Neurology Journal show art Neurology® at 75: The Evolution of the Neurology Journal

Neurology Minute

To celebrate 75 years of Neurology®, Dr. Chris Boes and Dr. José Merino discuss the journal’s history, its evolution, and what lies ahead for the future of Neurology®.   Read more about the first .   

info_outline
 
More Episodes

In the second episode of a four-part series on Rett syndrome, Dr. Stacey Clardy discusses the importance of early referrals, particularly during the regression phase. 

Show transcript: 

Dr. Stacey Clardy: 

This is the Neurology Minute. I'm Stacey Clardy from the Salt Lake City VA and the University of Utah. This is the second episode in a four-part series on Rett syndrome. Today, let's discuss when to refer and specifically early referral is absolutely critical in Rett syndrome, particularly during the regression phase. Any child, most often a girl with previously acquired developmental milestones who begins to lose language or lose purposeful hand use or develops stereotyped hand movements should prompt urgent neurologic evaluation. This would be referral to pediatric neurology, of course, and this should not wait for genetic confirmation. Early involvement of pediatric neurology allows for diagnostic clarification, anticipatory guidance, and coordination of care across systems. The genetic testing, typically with MECP2 sequencing and deletion or duplication analysis, this should be pursued early and if initial testing is negative but suspicion remains high, expanding that genetic evaluation is warranted. And beyond neurology, early engagement with developmental services, speech, occupational, and physical therapy should start before even a definitive diagnosis is necessarily established.

Rett syndrome is a multi-system disorder. So a care team is going to monitor for common comorbidities. This is not just epilepsy, but also gastrointestinal dysfunction, breathing abnormalities, and orthopedic complications. When delayed referrals occur, it's often due to attribution of regression to more common developmental conditions. Be sure to listen to the other Neurology Minute episodes in this series. We'll be back next time for our third episode, and we'll cover treatment options and ongoing management.